Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib and Statins DDI Study
NCT04608344Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration at Day 20, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at Day 20 and 1 more. Started Nov 2020; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04608344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608344.